Oculis Holding AG
NASDAQ:OCS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Oculis Holding AG
Total Receivables
Oculis Holding AG
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Oculis Holding AG
NASDAQ:OCS
|
Total Receivables
CHf1.8m
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Total Receivables
$9.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Total Receivables
$449.5k
|
CAGR 3-Years
124%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Total Receivables
CHf11.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Total Receivables
$3.3B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Oculis Holding AG
Glance View
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The company is headquartered in Zug, Zug and currently employs 28 full-time employees. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
See Also
What is Oculis Holding AG's Total Receivables?
Total Receivables
1.8m
CHF
Based on the financial report for Dec 31, 2025, Oculis Holding AG's Total Receivables amounts to 1.8m CHF.
What is Oculis Holding AG's Total Receivables growth rate?
Total Receivables CAGR 5Y
9%
Over the last year, the Total Receivables growth was 131%. The average annual Total Receivables growth rates for Oculis Holding AG have been 18% over the past three years , 9% over the past five years .
